Trial Profile
A phase 2 randomized, controlled trial of PEHRG214 [HRG-214] in HIV-infected patients with AIDS
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs HRG 214 (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Amplia Therapeutics Limited
- 13 Jul 2007 New trial record.